Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Apricus launches Virirec in Spain to treat erectile dysfunction
Virirec, Apricus’ novel topical on-demand treatment for erectile dysfunction ("ED") is also marketed in other European countries as Vitaros and in Belgium as Vytaros. This is the fifth
Virirec, Apricus’ novel topical on-demand treatment for erectile dysfunction ("ED") is also marketed in other European countries as Vitaros and in Belgium as Vytaros. This is the fifth
The world market for HAE reached $1.1bn in 2014 and has been growing at an average rate of 44% in the last three years, and analysts expect the
EirGen, based in Waterford, Ireland, was founded by two former executives of IVAX Pharmaceuticals, Tom Brennan and Patsy Carney. The company, situated in a state of the art
Upon issuance, the patent will provide additional intellectual property protection for MANF (mesencephalic-astrocyte-derived neurotrophic factor) protein therapy and cell therapy. The allowed patent claims cover compositions of matter
The Company’s Phase 3 protocol provides for a 25-week study with 300 HIV patients, which could start as early as 30 days after submission. The Company believes that
Results showed HUMIRA significantly lowered their risk of uncontrolled uveitis or vision loss. The results were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2015
"We are extremely pleased to now have orphan drug designation for MI-100 to treat Stargardt’s disease in place for Europe. This complements and reinforces our development program in
Cortex is a leader in developing drugs for respiratory disorders, particularly sleep apnea (both obstructive and central) and drug-induced respiratory depression. Premature infants exhibit frequent apneic events and
Both studies combine standard doses of gemcitabine or ifosfamide with escalating doses of aldoxorubicin. The combinations appear to be well tolerated, and even at the lowest dose level
The submission follows Merrimack’s recent filing of a new drug application (NDA) for this indication with the United States Food and Drug Administration (FDA). "Our coordinated U.S. and